Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Cautious Hold Rating on Becton Dickinson Amid Uncertainties in Waters Merger and Revenue Projections
- DoorDash, Southwest downgraded: Wall Street’s top analyst calls
- Strategic and Financial Gains Drive Buy Rating for Becton Dickinson Amid Reverse Morris Trust Deal
- Waters downgraded to Equal Weight from Overweight at Wells Fargo
- Becton Dickinson’s Hold Rating Amid Strategic Moves and Limited Immediate Upside